



# An Introduction to IP and Commercialisation - Important Things to Consider as a Researcher



**Dr. PAMELA TRANTER**  
Head of Translational  
Research Group,  
at TRO UCL



**Dr. MARK FISHER**  
Associate Director of  
BioPharm, UCL

- 3<sup>rd</sup> of February 2025, 2:00 PM (CET)
- MS Teams webinar [LINK](#)

**Dr. Pamela Tranter** joined the Translational Research Group in November 2014 and has been head of the group since Sept 2016. Pamela has led Thrombosis and Respiratory projects on multiple targets and is experienced in managing cross functional and global project teams.

Dr. Pamela Tranter obtained her PhD in Platelet Biochemistry from the Royal Free Hospital Medical School and has extensive experience of drug discovery in the pharmaceutical industry at Ciba-Geigy and Novartis. At Novartis, Pamela led the Respiratory Disease Ion Channel Group and implemented novel automated electrophysiology technologies enabling the prosecution of many diverse ion channel targets.

**Dr Mark Fisher** has management responsibility for the BioPharm patent portfolio and strategic business support for the BioPharm team. At the coalface, Mark manages the commercialisation of technology from the Institute of Ophthalmology and Moorfields Eye Hospital. He holds a first degree in industrial biology and a PhD in biochemistry and molecular biology from UCL, in association with one of the first biotechnology companies to be established in the academic sector.

Mark brings more than 25 years of experience in life sciences and healthcare licensing, new company development and securing investment from both the public and private sectors to his team. To date Mark has been responsible for the establishment of more than 20 new businesses in diagnostics, drug discovery, medical devices and therapeutics. As a certified lead auditor of ISO 13485, Mark has additional experience in quality management systems and the translation of technologies from research and design into manufacture at home and abroad.

